Skip to main content

Market Overview

Moderna Hires Harvard Stem Cell Researcher Jonathan Hoggatt as Director of Hematology: What You Need to Know

Moderna Hires Harvard Stem Cell Researcher Jonathan Hoggatt as Director of Hematology: What You Need to Know

Moderna, Inc. (NASDAQ: MRNA), which shot to prominence with its coronavirus vaccine program, is beefing up its research and development team.

What Happened: Jonathan Hoggatt, who was a principal faculty member at Harvard Stem Cell Institute, has joined Cambridge, Massachusetts-based Moderna as director of hematology, according to a Twitter post by the researcher.

He served as assistant professor at the Harvard Medical School's Hoggatt Lab, which works on tissue regeneration and stem cell biology, with a particular focus on translational research to enhance bone marrow transplantation.

Hoggatt has a master's degree in biology and a doctoral degree in hematology, and pursued a post-doctoral program in stem cell biology, his LinkedIn profile revealed.

Related Link: The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings

Why It's Important: After the resounding success with its coronavirus vaccine program, it's logical Moderna now turns its attention toward other programs.

The company has a rich pipeline, comprising investigational prophylactic vaccines against infectious diseases, secreted and cell therapeutic candidates, cancer vaccine candidates, regenerative therapeutic candidates and immuno-oncology candidates.

The immuno-oncology pipeline consists of two candidates, namely mRNA-2416 for lymphoma and a triplet candidate, codenamed mRNA-2752, both aimed at treating lymphoma and solid tumors.

The new appointment may be signaling Moderna's intent to focus on these candidates in a big way.

MRNA Price Action: In premarket trading Friday, Moderna shares were slipping 1.36% to $130.50.

Related Link: The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study

(Moderna's Cambridge, Massachusetts offices; photo by Fletcher via Wikimedia Commons)


Related Articles (MRNA)

View Comments and Join the Discussion!

Posted-In: Covid-19 medical research medicine research Stem CellBiotech News General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at